iwAL 2022

16–18 September 2022 | Nice, France

VJHemOnc is pleased to be the official media partner for the 4th International Workshop on Acute Leukemias (iwAL), which was held in Nice, France, on 17 – 18 September, 2022.

The workshop brought together leading international clinicians and researchers in an in-person forum to discuss the current status and recent advances in acute leukemias with the aim to optimize clinical care.

Clinical genomics AML SOC ALL novel strategies MRD Regulatory endpoints BPDCN & CMML ELN 2022 classifications AML novel strategies ALL T‐cell engagement AML immunotherapeutics

Session 1: Current challenges in clinical genomics

CHIP and clonal hematopoiesis in relation to AML

Koichi Takahashi The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States

Fitness of leukemic stem cells

Claudia Lengerke University Hospital Tübingen , Tübingen, Germany

Current challenges in clinical genomics

Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Genomics and their clinical application for secondary AML

Paresh Vyas Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

Session 2: What is the standard of care in AML in 2022?

Improving intensive chemotherapy approaches in frontline AML

Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States

Maintenance therapy for whom?

Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia

Which patients should have allogeneic transplants in 2022?

Charles Craddock University of Birmingham, Birmingham, United Kingdom

Optimal transplant conditioning regimen in AML

Alessandro Rambaldi University of Milan, Milan, Italy

Optimizing therapy in secondary AML/RWE of CPX‐351

Christina Rautenberg University Hospital Essen, Essen, Germany

Targeted approaches for IDH‐mutated AML ‐ venetoclax or IDHi?

Stéphane de Botton Gustave Roussy, Paris, France

Current approach for relapsed FLT3‐mutant AML

Jessica Altman Northwestern University, Chicago, IL, United States

Session 3: Novel treatment strategies in ALL

Innovation in the treatment of ALL

Daniel DeAngelo Dana-Farber Cancer Institute, Boston, MA, United States

Ponatinib combination strategies

Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Progress in treatment of AYA ALL

Nicolas Boissel Saint-Louis Hospital, Paris, France

Open questions in Ph+ ALL

Robin Foà Sapienza University of Rome, Italy

Updates in asparaginase treatment strategies

Rob Pieters Princess Máxima Center, Utrecht, Netherlands

Session 4: New frontiers in MRD
Part 1 – ALL clinical practice

MRD in adult Ph‐/BCR‐ABL‐negative ALL: how best to eradicate?

Nicola Gökbuget University Hospital Frankfurt, Frankfurt, Germany

Session 4: New frontiers in MRD
Part 2 – AML clinical practice

Single‐cell sequencing and clinical applicability in detection and therapy of AML

Catherine Smith University of California, San Francisco, San Francisco, CA, United States

Value of MRD assessment in non‐intensive regimens in AML

Farhad Ravandi MD Anderson Cancer Center, Houston, TX, United States

Novel approaches for integrating MRD into clinical trials

Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia

Session 5: Special session on regulatory endpoints in AML

The FDA’s perspective on regulatory endpoints in AML

Kelly Norsworthy Johns Hopkins Medicine, Baltimore, MD, United States

A clinician’s perspective on endpoints and drug development in AML

Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session 6: BPDCN & CMML

Updates in diagnosis, pathogenesis and future directions in BPDCN

Naveen Pemmaraju The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Updates in CMML diagnosis and treatment, future targets

Mrinal Patnaik Rochester, MN, United States

Session 7: ELN 2022 classifications

ELN 2022 classifications

Andrew Wei Alfred Hospital and Monash University, Melbourne, Australia

Session 8: Novel targets, combinations and treatments in AML
Part 1 – What is the next AML blockbuster?

Challenges in the treatment of high‐risk AML

Richard Stone Dana-Farber Cancer Institute, Boston, MA, United States

Doublet and triplet combinations in AML

Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Emerging novel antibody‐drug conjugates

Roland Walter Fred Hutchinson Cancer Research Center, Seattle, WA, United States

TP53 treatment strategies in AML

Thomas Cluzeau Central University Hospital of Nice, France

Menin inhibitors in AML

Eytan Stein Memorial Sloan Kettering Cancer Center, New York City, NY, United States

Anti‐CD47

David Sallman H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Session 8: Novel targets, combinations and treatments in AML
Part 2 – What do we know about drug resistance?

Understanding and overcoming resistance to IDHi

Paresh Vyas Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

Targeting resistance to venetoclax‐based therapies

Marina Konopleva Albert Einstein College of Medicine, New York City, NY, United States

Resistance to FLT3 inhibitors

Alexander Perl University of Pennsylvania, Philadelphia, PA, United States

Epigenetic therapies and Epitranscriptomics

Carsten Müller‐Tidow Heidelberg University Hospital, Heidelberg, Germany

Session 9: T‐cell engagement
Part 1 – roadmap on how to treat relapsed ALL

Use of monoclonal antibodies in the CAR T‐cell era

Nicola Gökbuget University Hospital Frankfurt, Frankfurt, Germany

Integration of immunotherapies into frontline ALL management

Elias Jabbour University of Texas MD Anderson Cancer Center, Houston, TX, United States

Session 9: T‐cell engagement
Part 2 – CAR-T in ALL

Predicting response to CAR‐T

Bijal Shah H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Tisagenlecleucel in B‐ALL

Sara Ghorashian Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

ZUMA‐3 and brexucabtagene autoleucel indication for adult ALL

Nicolas Boissel Saint-Louis Hospital, Paris, France

Session 10: Immunotherapeutics in AML

Pitfalls and future strategies for immunotherapies in AML

Marion Subklewe LMU Hospital Munich, Munich, Germany

CLL1‐CD33 cCAR‐T

Fang Liu Chengdu Military General Hospital, Sichuan, China

Novel targets for CAR‐T in AML

Michael Hudecek University of Würzburg, Würzburg, Germany

Immune checkpoint inhibitors in AML

Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States

Emerging NK cell‐based therapies in AML

Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Which CAR T‐cell strategy in AML has the most promise?

Saar Gill Perelman School of Medicine, Philadelphia, PA, United States

iwAL 2022 was supported by:

iwAL 2022

iwAL 2022

For the latest updates in AML & ALL, click below to explore our dedicated channels

Sign-up for our Newsletter!